Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery

Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery - Influence of human atrial natriuretic peptide on renal function during cardiac surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001440

Enrollment

700

Registered

2008-10-20

Start date

1997-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction, angina, valvular disease, thoracic aortic aneurysm

Interventions

Perioperative administration of hANP Perioperative non-administration of hANP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient undergoing cardiac surgery Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: renal impairment(Cr>1.3mg/dl) cardiogenic shock

Design outcomes

Primary

Measure	Time frame
mortality complication Incidence of postoperative acute renal failure maximum value and percent increase of Cr.	—

Secondary

Measure	Time frame
pre-op, 0,1,3,7 days after surgery: ANP, renin activity, angiotensin II, aldosterone, blood urea nitrogen (BUN), Cr, sodium (Na), osmotic pressure (Osm),Urinary Na (U-Na), urinary Cr (U-Cr), and osmotic pressure (U-osm) . pre-op, 0,1,3,7 days after surgery: creatinine clearance Ccr, fractional sodium excretion, free water clearance and renal failure index.	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026